about
GEMMs as preclinical models for testing pancreatic cancer therapiesMolecular Targeted Intervention for Pancreatic CancerSpotlights on immunological effects of reactive nitrogen species: When inflammation says nitric oxideCopper is required for oncogenic BRAF signalling and tumorigenesisEstrogen-dependent dynamic profile of eNOS-DNA associations in prostate cancerDrugging the undruggable RAS: Mission possible?Wild-Type Hras Suppresses the Earliest Stages of Tumorigenesis in a Genetically Engineered Mouse Model of Pancreatic Cancer.Downregulation of tetrahydrobiopterin inhibits tumor angiogenesis in BALB/c-nu mice with hepatocellular carcinoma.AMPK and Endothelial Nitric Oxide Synthase Signaling Regulates K-Ras Plasma Membrane Interactions via Cyclic GMP-Dependent Protein Kinase 2.Inducible nitric oxide synthase enhances disease aggressiveness in pancreatic cancer.Gasotransmitters in cancer: from pathophysiology to experimental therapy.The yin and yang of nitric oxide in cancer progression.Metabolic rewiring of pancreatic ductal adenocarcinoma: New routes to follow within the maze.Glucose-regulated protein 94 mediates cancer progression via AKT and eNOS in hepatocellular carcinoma.NO• and Pancreatic Cancer: A Complex Interaction with Therapeutic Potential.Nitric oxide increases the invasion of pancreatic cancer cells via activation of the PI3K-AKT and RhoA pathways after carbon ion irradiation.Intratumoral heterogeneity of ADAM23 promotes tumor growth and metastasis through LGI4 and nitric oxide signals.Treatment with the nitric oxide synthase inhibitor L-NAME provides a survival advantage in a mouse model of Kras mutation-positive, non-small cell lung cancer.Endothelial Nitric Oxide Synthase Traffic Inducer (NOSTRIN) is a Negative Regulator of Disease Aggressiveness in Pancreatic Cancer.Inhibition of endothelial nitric oxide synthase in cholangiocarcinoma cell lines - a new strategy for therapy.Role of Oxidative and Nitro-Oxidative Damage in Silver Nanoparticles Cytotoxic Effect against Human Pancreatic Ductal Adenocarcinoma Cells
P2860
Q26781848-072D2D39-8649-4B75-9BDF-D07BE077F0BBQ26798453-CEC247E0-93ED-4CF4-9F5B-A20C8511047DQ27694770-7D1E5E42-2A5E-4A2F-85EB-E64247BE9A4FQ28237892-26023856-83AF-4689-9F2F-494A2EFF8743Q34712579-A0E1090B-3EC4-4D45-9F07-6552A6423890Q35163434-179BDEBE-3109-41AD-B66C-756D4AC0D76AQ35801876-3C7707D8-5437-4ECD-84F8-C2F13C21C9B2Q37066679-1422C39E-8A7F-4DDF-B4B0-8796A422AEDFQ37448013-E6BEA1E4-2291-4288-92E0-DC1EEEFCE137Q37619697-9B3AF66C-DD61-4344-BCB4-F23F303C0A3AQ37656625-D392E0CC-F6CD-44AD-9658-D942FCA2BFD7Q38077081-D8D42ED2-BEBE-4E1F-9C4A-F94EC11C1421Q38366834-DB12D072-E8C7-411C-B7FB-DC8AB7436D57Q38825761-C6F226F4-D420-4275-BF18-6136172C21DBQ38832619-C4293E13-115D-433B-B741-9A95CA29EFD8Q38975626-E16EA2B9-B51D-443E-BFA0-AE6D0C686777Q39012270-D6DE4ECA-DC71-42B7-9F8E-6ED376CE29FAQ39543819-E74837D6-22FC-41F9-9F12-CA9E0283DF96Q48037743-677DB6E3-EDB9-400A-8036-5F39D40402F6Q52597485-54F285F4-8741-4FEF-A770-0EB30D4D3D55Q58773113-B5656D6E-228E-44BC-8C2D-722A248EE84B
P2860
description
2012 nî lūn-bûn
@nan
2012年の論文
@ja
2012年学术文章
@wuu
2012年学术文章
@zh-cn
2012年学术文章
@zh-hans
2012年学术文章
@zh-my
2012年学术文章
@zh-sg
2012年學術文章
@yue
2012年學術文章
@zh
2012年學術文章
@zh-hant
name
Targeting eNOS in pancreatic cancer.
@en
Targeting eNOS in pancreatic cancer.
@nl
type
label
Targeting eNOS in pancreatic cancer.
@en
Targeting eNOS in pancreatic cancer.
@nl
prefLabel
Targeting eNOS in pancreatic cancer.
@en
Targeting eNOS in pancreatic cancer.
@nl
P2093
P2860
P1433
P1476
Targeting eNOS in pancreatic cancer.
@en
P2093
Benjamin L Lampson
Brooke B Ancrile
Christopher M Counter
Diana M Cardona
Katharine S Barrientos
Matthew S Crowe
Meghan M Morrison
Michael J Shealy
Rebekah R White
S Disean Kendall
P2860
P304
P356
10.1158/0008-5472.CAN-12-0057
P407
P577
2012-06-27T00:00:00Z